Theralase closes C$ 3.56 million brokered private placement at C$ 0.24 per unit

• Theralase closed a brokered private placement, issuing 14,812,500 units at C$ 0.24 for gross proceeds of C$ 3.56 million.
• Each unit includes one common share, one warrant exercisable at C$ 0.32 until May 20, 2031.
• Proceeds target GLP toxicology work for Rutherrin and Ruvidar, working capital, general corporate purposes.
• Research Capital acted as sole agent, earning C$ 216,893 cash commission; 903,723 compensation options issued.
• Insiders bought 116,250 units for C$ 27,900, subject to a four-month hold.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theralase Technologies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608241701NEWSFILECNPR____20260824_311258_1) on August 24, 2026, and is solely responsible for the information contained therein.